JCOG0605_2B | R Documentation |
Kaplan-Meier digitized data from JCOG0605, figure 2B (PMID 27312053). A reported sample size of 180 for a primary endpoint of OS in lung cancer.
JCOG0605_2B
A data frame of 180 observations and 3 variables:
time | event time (in months) | |
event | PFS event indicator (0 : no event, 1 : event) |
|
arm | treatment arms (combination_chemotherapy, topotecan) | |
Goto K, Ohe Y, Shibata T, et al. Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2016; 17: 1147–57.
summary(JCOG0605_2B)
kmplot(JCOG0605_2B)
Add the following code to your website.
For more information on customizing the embed code, read Embedding Snippets.